Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?

作     者：Marco Dall’Agata Annagiulia Gramenzi Maurizio Biselli Mauro Bernardi 

作者机构：Semeiotica Medica - Policlinico S.Orsola-MalpighiDipartimento di Scienze Mediche e ChirurgicheUniversity of Bologna 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第28期

页      面：9253-9260页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

主　　题：Hepatitis C virus Liver transplantation Direct ant 

摘      要：Recurrence of hepatitis C virus(HCV)infection following liver transplantation(LT)is almost universal and can accelerate graft cirrhosis in up to 30%of *** development of effective strategies to treat or prevent HCV recurrence after LT remains a major challenge,considering the shortage of donor organs and the accelerated progression of HCV in LT *** antiviral therapy with pegylated-interferon plus ribavirin is the current treatment of choice for HCV LT recipients,even though the combination is not as effective as it is in immunocompetent patients.A sustained virological response in the setting of LT improves patient and graft survival,but this is only achieved in 30%-45%of patients and the treatment is poorly *** improve the efficacy of pre-and post-transplant antiviral therapy,a new class of potent direct-acting antiviral agents (DAAs)has been *** aim of this review is to summarize the use of DAAs in LT HCV ***,Cochrane Library,MEDLINE,EMBASE,Web of Science and clinical trial databases were searched for this *** date,only three clinical studies on the topic have been published and most of the available data are in abstract *** a moderately successful early virological response has been reported,DAA treatment regimens were associated with severe toxicity mitigating their potential ***,the ongoing nature of data,the lack of randomized studies,the small number of enrolled patients and the heterogeneity of these studies make the results largely anecdotal and *** conclusion,large welldesigned clinical studies on DAAs in HCV LT patients are required before these drugs can be recommended after transplantation.